BDA-366, a Bcl-2 BH4-selective antagonist, was found to induce conformational changes in the exposure of the BH3 domain and abrogate the anti-apoptotic function of Bcl-2, and further significantly anti-tumor activity without platelet reduction in lung cancer and diffuse large B-cell lymphoma [35, 36]. Here, BCL2 is linked to neoplasm.